Vijay Kedia, a veteran value investor, disclosed that his portfolio swelled to roughly ₹1,415 crore by August 2026, marking a 21% rise from the previous quarter. The gain comes as the broader market, anchored by the Sensex and Nifty, wrestles with mixed earnings and policy cues, but small‑cap stocks have been the standout performers, lifting the Nifty Small‑Cap index. Five of Kedia’s holdings posted double‑digit gains, with Neuland Laboratories leading the pack at a 53% surge, propelling the pharma‑related small‑cap segment.
Other notable winners included stocks that rallied between 30% and 55%, reinforcing the view that disciplined, fundamentals‑driven picks can outpace the broader indices. Conversely, Innovators Facade Systems slipped 37%, reminding investors that volatility remains a feature of niche sectors. The latest addition, Eimco Elecon, expands Kedia’s exposure to the engineering and infrastructure space, a sector poised to benefit from the government’s renewed focus on capital spending.
While the stock’s entry price suggests upside potential, retail investors should weigh the cyclical nature of infrastructure demand against the broader market’s risk appetite. For everyday investors, Kedia’s performance underscores the importance of diversification across high‑conviction small‑caps while staying vigilant about sector‑specific risks. Monitoring earnings momentum and policy developments can help replicate such returns without over‑relying on any single stock.